Skip to main content
SpringerLink
Log in

Interleukins 1 and 6 as main mediators of inflammation and cancer

  • Review
  • Published:
Biochemistry (Moscow) Aims and scope Submit manuscript

Abstract

The idea of a potential link between cancer and inflammation was first proposed by R. Virchow in the nineteenth century. However, clear evidence regarding a key role of inflammation in oncogenesis appeared only during the last decade. Now the tumor microenvironment is commonly considered as an obligatory and significant component of almost all types of cancer, and the cells infiltrating such microenvironment are a source of inflammatory cytokines. Such cytokines play a key role in regulating inflammation during both normal immune response and developing cancer. In this review, we explore the role of two inflammatory cytokines interleukin 1 and interleukin 6 in cancer development. These cytokines have pleiotropic effects on various cell types in the tumor microenvironment, particularly being able to regulate pro-oncogenic transcription factors NF-κB and STAT3. For this reason, such cytokines influence key parameters of oncogenesis, increasing cell resistance to apoptosis, proliferation of cancer cells, angiogenesis, invasion and malignancy as well as the ability of tumor cells to respond to anticancer therapy. Here we summarize novel experimental data regarding mechanisms underlying the interaction between chronic inflammation and malignant neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

APC:

adenoma polyposis coli gene

CAC:

colitis-associated cancer

HFD:

high fat diet

IL1:

interleukin 1

IL6:

interleukin 6

IL6R:

IL6 receptor

IL1R:

IL1 receptor

IL1Ra:

interleukin 1 receptor antagonist

LPS:

lipopolysaccharide

Th9:

T-helper type 9

Th17:

T-helper type 17

TLR:

Tolllike receptor

TNF:

tumor necrosis factor

References

  1. Mantovani, A., Romero, P., Palucka, A. K., and Marincola, F. M. (2008) Tumour immunity: effector response to tumour and role of the microenvironment, Lancet, 371, 771–783.

    Article  CAS  PubMed  Google Scholar 

  2. Balkwill, F., and Coussens, L. M. (2004) Cancer: an inflammatory link, Nature, 431, 405–406.

    Article  CAS  PubMed  Google Scholar 

  3. Coussens, L. M., and Werb, Z. (2002) Inflammation and cancer, Nature, 420, 860–867.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Galon, J., Costes, F., Sanchez-Cabo, A., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoue, F., Bruneval, P., Cugnenc, P. H., Trajanoski, Z., Fridman, W. H., and Pages, F. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960–1964.

    CAS  Google Scholar 

  5. Kuraishy, A., Karin, M., and Grivennikov, S. I. (2011) Tumor promotion via injuryand death-induced inflammation, Immunity, 35, 467–477.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Osawa, E., Nakajima, A., Fujisawa, T., Kawamura, Y. I., Toyama-Sorimachi, N., Nakagama, H., and Dohi, T. (2006) Predominant T-helper type 2-inflammatory responses promote murine colon cancers, Int. J. Cancer, 118, 2232–2236.

    Article  CAS  PubMed  Google Scholar 

  7. Canavan, C., Abrams, K. R., and Mayberry, J. (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease, Aliment. Pharmacol. Ther., 23, 1097–1104.

    Article  CAS  PubMed  Google Scholar 

  8. Grivennikov, S. I., Greten, F. R., and Karin, M. (2010) Immunity, inflammation, and cancer, Cell, 140, 883–899.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Grivennikov, S. I. (2013) Inflammation and colorectal cancer: colitis-associated neoplasia, Semin. Immunopathol., 35, 229–244.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G. Y., Osterreicher, C. H., Hung, K. E., Datz, C., Feng, Y., Fearon, E. R., Oukka, M., Tessarollo, L., Coppola, V., Yarovinsky, F., Cheroutre, H., Eckmann, L., Trinchieri, G., and Karin, M. (2012) Adenoma-linked barrier defects and microbial products drive IL23/IL17-mediated tumour growth, Nature, 491, 254–258.

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Grivennikov, S. I., and Karin, M. (2010) Inflammation and oncogenesis: a vicious connection, Curr. Opin. Genet. Dev., 20, 65–71.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation, Cell, 144, 646–674.

    Article  CAS  PubMed  Google Scholar 

  13. Greten, F. R., and Karin, M. (2005) NF-κB: linking inflammation and immunity to cancer development and progression, Nat. Rev. Immunol., 5, 749–759.

    Article  PubMed  Google Scholar 

  14. Natoli, G. (2009) Control of NF-kappaB-dependent transcriptional responses by chromatin organization, Cold Spring Harb. Perspect. Biol., 1, a000224.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Barish, G. D., Yu, R. T., Karunasiri, M., Ocampo, C. B., Dixon, J., Benner, C., Dent, A. L., Tangirala, R. K., and Evans, R. M. (2010) Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response, Genes Dev., 24, 2760–2765.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Smale, S. T. (2011) Hierarchies of NF-kappaB target-gene regulation, Nat. Immunol., 12, 689–694.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Atreya, R., Mudter, J., Finotto, S., Mullberg, J., Jostock, T., Wirtz, S., Schutz, M., Bartsch, B., Holtmann, M., Becker, C., Strand, D., Czaja, J., Schlaak, J. F., Lehr, H. A., Autschbach, F., Schurmann, G., Nishimoto, N., Yoshizaki, K., Ito, H., Kishimoto, T., Galle, P. R., RoseJohn, S., and Neurath, M. F. (2000) Blockade of interleukin 6 trans-signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo, Nat. Med., 6, 583–588.

    Article  CAS  PubMed  Google Scholar 

  18. Karin, M., Cao, Y., Greten, F. R., and Li, Z. W. (2002) NF-κB in cancer: from innocent bystander to major culprit, Nat. Rev. Cancer, 2, 301–310.

    Article  CAS  PubMed  Google Scholar 

  19. Karin, M., and Lin, A. (2002) NF-κB at the crossroads of life and death, Nat. Immunol., 3, 221–227.

    Article  CAS  PubMed  Google Scholar 

  20. Karin, M. (2009) NF-kappaB as a critical link between inflammation and cancer, Cold Spring Harb. Perspect. Biol., 1, a000141.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Atreya, I., Atreya, R., and Neurath, M. F. (2008) NFkappaB in inflammatory bowel disease, J. Intern. Med., 263, 591–596.

    Article  CAS  PubMed  Google Scholar 

  22. Nagasaki, T., Hara, M., Nakanishi, H., Takahashi, H., Sato, M., and Takeyama, H. (2014) Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction, Br. J. Cancer, 110, 469–478.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Louis, P., Hold, G. L., and Flint, H. J. (2014) The gut microbiota, bacterial metabolites and colorectal cancer, Nat. Rev. Microbiol., 12, 661–672.

    Article  CAS  PubMed  Google Scholar 

  24. Yu, H., Pardoll, D., and Jove, R. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3, Nat. Rev. Cancer, 9, 798–809.

    Article  CAS  PubMed  Google Scholar 

  25. Kishimoto, T. (2005) Interleukin-6: from basic science to medicine–40 years in immunology, Annu. Rev. Immunol., 23, 1–21.

    Article  CAS  PubMed  Google Scholar 

  26. Kishimoto, T. (1989) The biology of interleukin-6, Blood, 74, 1–10.

    CAS  PubMed  Google Scholar 

  27. Neurath, M. F. (2014) Cytokines in inflammatory bowel disease, Nat. Rev. Immunol., 14, 329–342.

    Article  CAS  PubMed  Google Scholar 

  28. Calabrese, L. H., and Rose-John, S. (2014) IL-6 biology: implications for clinical targeting in rheumatic disease, Nat. Rev. Rheumatol., 10, 720–727.

    Article  CAS  PubMed  Google Scholar 

  29. Hirano, T., Ishihara, K., and Hibi, M. (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors, Oncogene, 19, 2548–2556.

    CAS  PubMed  Google Scholar 

  30. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway, Biochem. J., 334, 297–314.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Wang, Y., Van Boxel-Dezaire, A. H., Cheon, H., Yang, J., and Stark, G. R. (2013) STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor, Proc. Natl. Acad. Sci. USA, 110, 16975–16980.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Yang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E., and Stark, G. R. (2007) Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB, Genes Dev., 21, 1396–1408.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., Blosser, R. L., Tam, A. J., Bruno, T., Zhang, H., Pardoll, D., and Kim, Y. (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients, J. Clin. Invest., 123, 1580–1589.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Schaper, F., and Rose-John, S. (2015) Interleukin-6: biology, signaling and strategies of blockade, Cytokine Growth Factor Rev., 26, 475–487.

    Article  CAS  PubMed  Google Scholar 

  35. Rose-John, S. (2014) The biology of interleukin-6 in the 21st century, Semin. Immunol., 26, 1.

    Article  CAS  PubMed  Google Scholar 

  36. Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., Ito, H., Nishimoto, N., Yoshizaki, K., Kishimoto, T., Galle, P. R., Blessing, M., Rose-John, S., and Neurath, M. F. (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling, Immunity, 21, 491–501.

    Article  CAS  PubMed  Google Scholar 

  37. Matsumoto, S., Hara, T., Mitsuyama, K., Yamamoto, M., Tsuruta, O., Sata, M., Scheller, J., Rose-John, S., Kado, S., and Takada, T. (2010) Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model, J. Immunol., 184, 1543–1551.

    Article  CAS  PubMed  Google Scholar 

  38. Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G. Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., and Karin, M. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer, Cancer Cell, 15, 103–113.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Rose-John, S., Scheller, J., Elson, G., and Jones, S. A. (2006) Interleukin-6 biology is coordinated by membranebound and soluble receptors: role in inflammation and cancer, J. Leukoc. Biol., 80, 227–236.

    Article  CAS  PubMed  Google Scholar 

  40. Jones, S. A., Richards, P. J., Scheller, J., and Rose-John, S. (2005) IL-6 trans-signaling: the in vivo consequences, J. Interferon Cytokine Res., 25, 241–253.

    Article  CAS  PubMed  Google Scholar 

  41. Tawara, K., Oxford, J. T., and Jorcyk, C. L. (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies, Cancer Manag. Res., 3, 177–189.

    PubMed Central  CAS  PubMed  Google Scholar 

  42. Chang, Q., Bournazou, E., Sansone, P., Berishaj, M., Gao, S. P., Daly, L., Wels, J., Theilen, T., Granitto, S., Zhang, X., Cotari, J., Alpaugh, M. L., De Stanchina, E., Manova, K., Li, M., Bonafe, M., Ceccarelli, C., Taffurelli, M., Santini, D., Altan-Bonnet, G., Kaplan, R., Norton, L., Nishimoto, N., Huszar, D., Lyden, D., and Bromberg, J. (2013) The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis, Neoplasia, 15, 848–862.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Guo, Y., Xu, F., Lu, T., Duan, Z., and Zhang, Z. (2012) Interleukin-6 signaling pathway in targeted therapy for cancer, Cancer Treat. Rev., 38, 904–910.

    Article  CAS  PubMed  Google Scholar 

  44. Rossi, J. F., Lu, Z. Y., Jourdan, M., and Klein, B. (2015) Interleukin-6 as a therapeutic target, Clin. Cancer Res., 21, 1248–1257.

    Article  CAS  PubMed  Google Scholar 

  45. Nguyen, D. P., Li, J., and Tewari, A. K. (2014) Inflammation and prostate cancer: the role of interleukin 6 (IL-6), BJU Int., 113, 986–992.

    Article  CAS  PubMed  Google Scholar 

  46. Baltgalvis, K. A., Berger, F. G., Pena, M. M., Davis, J. M., Muga, S. J., and Carson, J. A. (2008) Interleukin-6 and cachexia in ApcMin/+ mice, Am. J. Physiol. Regul. Integr. Comp. Physiol., 294, 393–401.

    Article  Google Scholar 

  47. He, G., Yu, G. Y., Temkin, V., Ogata, H., Kuntzen, C., Sakurai, T., Sieghart, W., Peck-Radosavljevic, M., Leffert, H. L., and Karin, M. (2010) Hepatocyte IKKbeta/NFkappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation, Cancer Cell, 17, 286–297.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., and Karin, M. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production, Science, 317, 121–124.

    Article  CAS  PubMed  Google Scholar 

  49. He, G., Dhar, D., Nakagawa, H., Font-Burgada, J., Ogata, H., Jiang, Y., Shalapour, S., Seki, E., Yost, S. E., Jepsen, K., Frazer, K. A., Harismendy, O., Hatziapostolou, M., Iliopoulos, D., Suetsugu, A., Hoffman, R. M., Tateishi, R., Koike, K., and Karin, M. (2013) Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling, Cell, 155, 384–396.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. He, G., and Karin, M. (2011) NF-kappaB and STAT3–key players in liver inflammation and cancer, Cell Res., 21, 159–168.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Calle, E. E. (2007) Obesity and cancer, BMJ, 335, 1107–1108.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Kaaks, R. (2004) Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence, Novartis Found. Symp., 262, 247–260; discussion, 260-268.

    CAS  PubMed  Google Scholar 

  53. El-Serag, H. B., and Rudolph, K. L. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis, Gastroenterology, 132, 2557–2576.

    Article  CAS  PubMed  Google Scholar 

  54. Park, E. J., Lee, J. H., Yu, G. Y., He, G., Ali, S. R., Holzer, R. G., Osterreicher, C. H., Takahashi, H., and Karin, M. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression, Cell, 140, 197–208.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D. R., Miles, J. M., Yudkin, J. S., Klein, S., and Coppack, S. W. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo, J. Clin. Endocrinol. Metab., 82, 4196–4200.

    CAS  PubMed  Google Scholar 

  56. Fried, S. K., Bunkin, D. A., and Greenberg, A. S. (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid, J. Clin. Endocrinol. Metab., 83, 847–850.

    CAS  PubMed  Google Scholar 

  57. Garlanda, C. (2013) The interleukin-1 family: back to the future, Immunity, 39, 1003–1018.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Apte, R. N., and Voronov, E. (2008) Is interleukin-1 a good or bad “guy” in tumor immunobiology and immunotherapy? Immunol. Rev., 222, 222–241.

    Article  CAS  PubMed  Google Scholar 

  59. Kawai, T., and Akira, S. (2007) TLR signaling, Semin. Immunol., 19, 24–32.

    Article  CAS  PubMed  Google Scholar 

  60. Carpenter, S., and O’Neill, L. A. (2007) How important are Toll-like receptors for antimicrobial responses? Cell Microbiol., 9, 1891–1901.

    Article  CAS  PubMed  Google Scholar 

  61. Fettelschoss, A., Kistowska, M., LeibundGut-Landmann, S., Beer, H. D., Johansen, P., Senti, G., Contassot, E., Bachmann, M. F., French, L. E., Oxenius, A., and Kundig, T. M. (2011) Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression, Proc. Natl. Acad. Sci. USA, 108, 18055–1860.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Rider, P., Carmi, Y., Guttman, O., Braiman, A., Cohen, I., Voronov, E., White, M. R., Dinarello, C. A., and Apte, R. N. (2011) IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation, J. Immunol., 187, 4835–4843.

    Article  CAS  PubMed  Google Scholar 

  63. Gross, O., Yazdi, A. S., Thomas, C. J., Masin, M., Heinz, L. X., Guarda, G., Quadroni, M., Drexler, S. K., and Tschopp, J. (2012) Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1, Immunity, 36, 388–400.

    Article  CAS  PubMed  Google Scholar 

  64. Nakae, S., Saijo, S., Horai, R., Sudo, K., Mori, S., and Iwakura, Y. (2003) IL-17 production from activated T-cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist, Proc. Natl. Acad. Sci. USA, 100, 5986–5990.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Carmi, Y., Rinott, G., Dotan, S., Elkabets, M., Rider, P., Voronov, E., and Apte, R. N. (2011) Microenvironmentderived IL-1 and IL-17 interact in the control of lung metastasis, J. Immunol., 186, 3462–3471.

    Article  CAS  PubMed  Google Scholar 

  66. Voronov, E., Dotan, S., Krelin, Y., Song, X., Elkabets, M., Carmi, Y., Rider, P., Idan, C., Romzova, M., Kaplanov, I., and Apte, R. N. (2013) Unique versus redundant functions of IL-1alpha and IL-1beta in the tumor microenvironment, Front Immunol., 4, 177.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Carmi, Y., Dotan, S., Rider, P., Kaplanov, I., White, M. R., Baron, R., Abutbul, S., Huszar, M., Dinarello, C. A., Apte, R. N., and Voronov, E. (2013) The role of IL-1beta in the early tumor cell-induced angiogenic response, J. Immunol., 190, 3500–3509.

    Article  CAS  PubMed  Google Scholar 

  68. Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., and Apte, R. N. (2003) IL-1 is required for tumor invasiveness and angiogenesis, Proc. Natl. Acad. Sci. USA, 100, 2645–2650.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Dinarello, C. A. (2006) The paradox of pro-inflammatory cytokines in cancer, Cancer Metastasis Rev., 25, 307–313.

    Article  CAS  PubMed  Google Scholar 

  70. Dinarello, C. A. (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases, Blood, 117, 3720–3732.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  71. Finnegan, A., and Doodes, P. D. (2008) Pathways for interleukin-1-driven arthritis, Arthritis Rheum., 58, 3283–3285.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Apte, R. N., Dvorkin, T., Song, X., Fima, E., Krelin, Y., Yulevitch, A., Gurfinkel, R., Werman, A., White, R. M., Argov, S., Shendler, Y., Bjorkdahl, O., Dohlsten, M., Zoller, M., Segal, S., and Voronov, E. (2000) Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness, Adv. Exp. Med. Biol., 479, 277–288.

    Article  CAS  PubMed  Google Scholar 

  73. Voronov, E., Carmi, Y., and Apte, R. N. (2014) The role IL-1 in tumor-mediated angiogenesis, Front. Physiol., 5, 114.

    Article  PubMed Central  PubMed  Google Scholar 

  74. Apte, R. N., Krelin, Y., Song, X., Dotan, S., Recih, E., Elkabets, M., Carmi, Y., Dvorkin, T., White, R. M., Gayvoronsky, L., Segal, S., and Voronov, E. (2006) Effects of micro-environmentand malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour–host interactions, Eur. J. Cancer, 42, 751–759.

    Article  CAS  PubMed  Google Scholar 

  75. Apte, R. N., Dotan, S., Elkabets, M., White, M. R., Reich, E., Carmi, Y., Song, X., Dvozkin, T., Krelin, Y., and Voronov, E. (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor–host interactions, Cancer Metastasis Rev., 25, 387–408.

    Article  CAS  PubMed  Google Scholar 

  76. Salcedo, R., Worschech, A., Cardone, M., Jones, Y., Gyulai, Z., Dai, R. M., Wang, E., Ma, W., Haines, D., O’Huigin, C., Marincola, F. M., and Trinchieri, G. (2010) MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18, J. Exp. Med., 207, 1625–1636.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Vegran, F., Berger, H., Boidot, R., Mignot, G., Bruchard, M., Dosset, M., Chalmin, F., Rebe, C., Derangere, V., Ryffel, B., Kato, M., Prevost-Blondel, A., Ghiringhelli, F., and Apetoh, L. (2014) The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells, Nat. Immunol., 15, 758–766.

    Article  CAS  PubMed  Google Scholar 

  78. Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S., Hayman, S. R., Russell, S. J., Buadi, F. K., Geyer, S. M., Campbell, M. E., Kyle, R. A., Rajkumar, S. V., Greipp, P. R., Kline, M. P., Xiong, Y., Moon-Tasson, L. L., and Donovan, K. A. (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1 beta-induced interleukin 6 production and the myeloma proliferative component, Mayo Clin. Proc., 84, 114–122.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Lust, J. A., and Donovan, K. A. (1999) The role of interleukin-1 beta in the pathogenesis of multiple myeloma, Hematol. Oncol. Clin. North Am., 13, 1117–1125.

    Article  CAS  PubMed  Google Scholar 

  80. Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W. H., Pages, F., and Galon, J. (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer, Cancer Res., 71, 1263–1271.

    CAS  PubMed  Google Scholar 

  81. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., and Kuchroo, V. K. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T-cells, Nature, 441, 235–238.

    Article  CAS  PubMed  Google Scholar 

  82. Mangan, P. R., Harrington, L. E., O’Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., and Weaver, C. T. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage, Nature, 441, 231–234.

    Article  CAS  PubMed  Google Scholar 

  83. Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., and Littman, D. R. (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ Thelper cells, Cell, 126, 1121–1133.

    Article  CAS  PubMed  Google Scholar 

  84. Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L., Shah, B., Panopoulos, A. D., Schluns, K. S., Watowich, S. S., Tian, Q., Jetten, A. M., and Dong, C. (2008) T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma, Immunity, 28, 29–39.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Mathur, A. N., Chang, H. C., Zisoulis, D. G., Stritesky, G. L., Yu, Q., O’Malley, J. T., Kapur, R., Levy, D. E., Kansas, G. S., and Kaplan, M. H. (2007) Stat3 and Stat4 direct development of IL-17-secreting Th cells, J. Immunol., 178, 4901–4907.

    Article  CAS  PubMed  Google Scholar 

  86. Coward, J., Kulbe, H., Chakravarty, P., Leader, D. A., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J. A., Vermeulin, J., Singh, N., Avril, N. E., Cummings, J., Rexhepaj, E., Jirstrom, K., Gallagher, W. M., Brennan, D. J., McNeish, I. A., and Balkwill, F. R. (2011) Interleukin-6 as a therapeutic target in human ovarian cancer, Clin. Cancer Res., 17, 6083–6096.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  87. Voorhees, P. M., Manges, R. F., Sonneveld, P., Jagannath, S., Somlo, G., Krishnan, A., Lentzsch, S., Frank, R. C., Zweegman, S., Wijermans, P. W., Orlowski, R. Z., Kranenburg, B., Hall, B., Casneuf, T., Qin, X., Van De Velde, H., Xie, H., and Thomas, S. K. (2013) A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma, Br. J. Haematol., 161, 357–366.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, Cancer Prevention and Control program, 333 Cottman Avenue, Philadelphia, PA, USA

    O. S. Dmitrieva & S. I. Grivennikov

  2. Institute of Immunology, Federal Medicobiological Agency of Russia, 115478, Moscow, Russia

    O. S. Dmitrieva, I. P. Shilovskiy & M. R. Khaitov

  3. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia

    S. I. Grivennikov

Authors
  1. O. S. Dmitrieva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. P. Shilovskiy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. R. Khaitov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. I. Grivennikov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. I. Grivennikov.

Additional information

Original Russian Text © O. S. Dmitrieva, I. P. Shilovskiy, M. R. Khaitov, S. I. Grivennikov, 2016, published in Biokhimiya, 2016, Vol. 81, No. 2, pp. 166–178.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dmitrieva, O.S., Shilovskiy, I.P., Khaitov, M.R. et al. Interleukins 1 and 6 as main mediators of inflammation and cancer. Biochemistry Moscow 81, 80–90 (2016). https://doi.org/10.1134/S0006297916020024

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0006297916020024

Key words

Search

Navigation